Israel's IceCure Medical H1 revenue rises on higher system, probe sales

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
• Wall Street's median 12-month price target for Icecure Medical Ltd is $30.00, about 754.7% above its August 11 closing price of $3.51

The company ended H1 2026 with $12 mln in cash after multiple financings.

IceCure expects continued investment in its U.S. commercial organization and international expansion. It also plans to expand the CHoICE Study to more U.S. clinical sites and increase patient enrollment, and said it anticipates growing physician adoption and broader commercialization of the ProSense system.

The company expanded its U.S. commercial footprint with after FDA clearance.